Fig 2: The effects of UBE2J1 knockdown (A) and overexpression (B) on the expression of EMT-related and immune-related proteins in CAOV3 cells. All the experiments were performed in triplicate. ***p < 0.001

Fig 3: Repression of UBE2J1 inhibits ovarian cancer cell growth in vivo. A OVCAR3 cells transfected with sh-UBE2J1 or sh-NC were subcutaneously injected into right armpits of nude mice. Sample size = 5. B Comparison of tumor growth between sh-NC and sh-UBE2J1 group. C Comparison of tumor weight between sh-NC and sh-UBE2J1 group. **p < 0.01, ***p < 0.001

Fig 4: Expression of UBE2J1 in HGSOC tissues and cell lines. A The expression of UBE2J1 in plasma cell subclusters determined via scRNA-seq. B The expression of UBE2J1 following pseudotime in the scRNA-seq analysis. C The expression of UBE2J1 in the high- and low-plasma cell-related score groups. D mRNA expression of UBE2J1 in normal ovarian tissues and cancer tissues by qPCR. E, Representative images of immunofluorescence staining used to detect UBE2J1 expression in normal ovarian tissues (left) and cancer tissues (right). F Representative images of western blots showing the expression levels of UBE2J1 in normal ovarian surface epithelial cell lines (IOSE-80) and HGSOC cell lines (CAOV3, OVCAR3 and A2780). **p < 0.01, ***p < 0.001

Fig 5: Effect of UBE2J1 knockdown or overexpression on the expression of E-cadherin and PDCD1 in CAOV3 cells. Representative images of immunofluorescence with specific antibodies. All the experiments were performed in triplicate. ***p < 0.001